摘要
目的：探讨β受体阻滞剂美托洛尔（商品名倍他乐克）治疗慢性充血性心力衰竭（CHF）的临床疗效及应用时机。方法：将127例充血性心力衰竭患者随机分成观察组65例，对照组62例，均予强心、利尿、血管紧张素转换酶抑制荆等治疗，观察组加用倍他乐克。观察临床疗效、不良反应及应用时机。结果：观察组与对照组的总有效率分别为89．47％与75．81％，两组比较差异有显著性意义（P〈0．05）；与对照组及治疗6个月后比较左室后壁厚度（LVPWT）、左室射血分数（LVEF）的差异有显著性意义（P〈0．05）；两组患者不良反应的发生率无显著性差异（P〉0．05）。结论：及早应用美托洛尔治疗充血性心力衰竭安全有效，其长期疗效优于短期疗效。
Objective ：To Study on Application of the time on Chronic Heart Failure Patients with β -blocker Objective To Observe the Clinical Curative Effect and Application of the Time of β - blocker metoprolol （ product namebetaloc） on Congestive Heart Failure （CHF.）. Methods ： The 127 congestive heart failure patients were divided into two groups randomly,one was the observer group（65patients） ,the other was the control group（62 patients）. Both of them were treated with heart -beat strengthen, diuresis, and angiotensin converting enzyme inhibitor. In addition, the patients of observer group were treated with β - blocker betaloc. To observe clinical curative efect,adverse reactions and application of the time. Results ：The total efective rate of observer group and control group were 89. 47% and 75.81% respectively （ P 〈 0.05 ） ; to compare the uhrasonic cardiogram parameter of observer group patients with it of control group after 6 months treatment, there was conspicuous diference in the tw o groups, such as left ventricular posterior wall thickness（LVPWT） and left ventricular ejection fraction（LVEF） （ P 〈 0.05 ） ; Two groups of patients the incidence of adverse reactions was no significant difference （P 〉 0.05 ）. Conclusion ：Early application of metoproloU on congestive heart failure（CHF） was safe and efective, the longterm efect surpassed short -term efect.
